Not So Different: Why You Should Keep Your Eye on Ophthalmology Biosimilars

We spoke with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, about the status of ophthalmology biosimilars and her opinions on what needs to be accomplished for these agents to flourish.

Recently, one of our Advisory Board members, Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, wrote an opinion piece on the status of ophthalmology medications and the potential for ophthalmology biosimilars. We spoke with her to learn more about this topic and her opinions on what needs to be done to accelerate biosimilar use in this growing therapeutic area.

To read more on Dr. Oskouei's contributor piece, click here.

To learn more about Cardinal Health, click here.

Related Videos
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Ian Henshaw
banner for the ophthalmology linkedin live event sponsored by the samsung bioepis in partnership with the center for biosimilars
Paul Reider
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Sonia T. Oskouei, PharmD, MS
Polpharma Biologics
Sonia T. Oskouei, PharmD, BCMAS, DPLA, (left) and CfB's Tony Hagen (right)
George Williams, MD, (left) and CfB's Tony Hagen (right)
Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Related Content
© 2023 MJH Life Sciences

All rights reserved.